Alligator Bioscience launches ALLIGATOR-FAB™ – a novel human antibody library
Lund, Sweden, December 10, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced the completion of a novel proprietary human ...
Approved IND for Alligator Bioscience’s CD40-targeting antibody mitazalimab
Lund, Sweden, December 4, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced an approved IND (Investigational new Drug) f ...
Nomination Committee appointed in respect of AGM 2021 in Alligator Bioscience AB
Lund, Sweden, November 20, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that the Nomination Committee in preparatio ...
Aptevo Therapeutics and Alligator Bioscience advancing the bispecific 4-1BBx5T4 antibody ALG.APV-527 into Phase I clinical development
Lund, Sweden and Seattle, WA – November 16, 2020 – Alligator Bioscience (“Alligator”) (Nasdaq Stockholm: ATORX), a biotechnology company dev ...
Alligator Bioscience presents at the SITC 35th Annual Meeting
Three projects showcased – ATOR-1015, ALG.APV-527 and Neo-X-Prime – Lund, Sweden, November 9, 2020 – Alligator Bioscience (N ...
Alligator Bioscience presents the CD40 antibody mitazalimab at the World Immunotherapy Congress 2020
Strong benchmark to competitor CD40 antibodies Lund, Sweden, November 5, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announc ...
Predicted therapeutic range dose levels reached in ATOR-1017 Phase I
Lund, Sweden, October 27, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced additional positive interim safety data from ...
Alligator Bioscience AB (publ): Interim report January-September 2020
Encouraging clinical safety data for ATOR-1017 The Phase I study with ATOR-1017 has progressed exceptionally well and in August we presented ...
Alligator Bioscience focuses on ATOR-1017 and mitazalimab
Lund, Sweden, October 22, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced the decision to focus its resources on the t ...